Alimera Sciences, Inc. (NASDAQ:ALIM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, July 13th.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
A number of other equities analysts have also recently weighed in on ALIM. Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They set a “buy” rating and a $4.00 price target on the stock. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Cowen and Company reissued a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research report on Tuesday, July 11th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Alimera Sciences currently has a consensus rating of “Hold” and an average target price of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) traded up 1.36% during midday trading on Thursday, hitting $1.49. The stock had a trading volume of 119,817 shares. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.77. The stock has a 50-day moving average of $1.45 and a 200 day moving average of $1.39. The stock’s market cap is $97.57 million.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to analyst estimates of $10.20 million. During the same period in the prior year, the firm posted ($0.17) EPS. Alimera Sciences’s revenue was up 8.3% on a year-over-year basis. Analysts anticipate that Alimera Sciences will post ($0.21) EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of ALIM. JW Asset Management LLC boosted its stake in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. Kennedy Capital Management Inc. bought a new stake in Alimera Sciences during the first quarter valued at approximately $467,000. PNC Financial Services Group Inc. boosted its stake in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares in the last quarter. Finally, KCG Holdings Inc. boosted its stake in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares in the last quarter. 43.58% of the stock is currently owned by institutional investors and hedge funds.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Alimera Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alimera Sciences Inc. and related companies.